biostudies-literatureUnknown69Hernando-Calvo A<h4>Background</h4>To date, economic analyses of tissue-based next generation sequencing genomic profiling (NGS) for advanced solid tumors have typically required models with assumptions, with little real-world evidence on overall survival (OS), clinical trial enrollment or end-of-life quality of care.<h4>Methods</h4>Cost consequence analysis of NGS testing (555 or 161-gene panels) for advanced solid tumors through the OCTANE clinical trial (NCT02906943). This is a longitudinal, propensity score-matched retrospective cohort study in Ontario, Canada using linked administrative data. Patients enrolled in OCTANE at Princess Margaret Cancer Centre from August 2016 until March 2019 were matched with contemporary patients without large gene panel testing from across Ontario not enrolled in OCTANEClinicalMedicine102443https://www.ebi.ac.uk/biostudies/studies/S-EPMC10876574biostudies-literatureImpact on costs and outcomes of multi-gene panel testing for advanced solid malignancies: a cost-consequence analysis using linked administrative data.PMC10876574Abdul Razak ARPugh TJAmir EGyawali BEarle CCNguyen PBedard PLWilliams CRegier DAMittmann NHernando-Calvo AWilson BChan KKWStockley TLHanna TPYu CWeymann DSaleh RRSabatini PSpreafico AIsaranuwatchai WKain DSiu LLfalseImpact on costs and outcomes of multi-gene panel testing for advanced solid malignancies: a cost-consequence analysis using linked administrative data.<h4>Background</h4>To date, economic analyses of tissue-based next generation sequencing genomic profiling (NGS) for advanced solid tumors have typically required models with assumptions, with little real-world evidence on overall survival (OS), clinical trial enrollment or end-of-life quality of care.<h4>Methods</h4>Cost consequence analysis of NGS testing (555 or 161-gene panels) for advanced solid tumors through the OCTANE clinical trial (NCT02906943). This is a longitudinal, propensity score-matched retrospective cohort study in Ontario, Canada using linked administrative data. Patients enrolled in OCTANE at Princess Margaret Cancer Centre from August 2016 until March 2019 were matched with contemporary patients without large gene panel testing from across Ontario not enrolled in OCTAN2024-01-01T00:00:00Z2024 Mar2026-06-09T07:05:24.409Z2025-04-19T07:36:13.508ZS-EPMC108765743838007110.1016/j.eclinm.2024.102443